JIN-001 / J Ints Bio, UT MD Anderson Cancer Center - LARVOL DELTA

Synergistic anti-proliferative effects of JIN-001, a novel HSP90 selective inhibitor, in combination with platinum-based drugs in ovarian cancer cell lines (AACR 2025) - "Here, We investigated the anti-proliferative effects of JIN-001, a selective HSP90i, combined with platinum-based drugs in OC cell lines.Material and We examined the co-treatment effects of JIN-001 and paclitaxel (PTX) or cisplatin (Cis, platinum-based) on viability in OC cell lines (OV90, TOV21G, and OVCAR3) and drug-resistance sublines (OV90/PTX200, TOV21G/PTX100, and OVCAR3-CisR). The combination of JIN-001 with PTX or Cis enhanced anti-proliferative effects and reduced IC50 in OC cell lines and drug-resistant sublines compared to monotherapy. This suggests JIN-001's potential as a combination therapy with platinum-based drugs in OC patients. Further studies are needed to examine whether the combination therapy of JIN-001 and the conventional drugs decelerates the tumor's ability to adapt and develop drug resistance."

Combination therapy • Preclinical • Gynecologic Cancers • Oncology • Ovarian Cancer • Solid Tumor • CDC37 • HSP90AA1 • PRDX2

'JIN-001': An Innovative New Drug Targeting Refractory Ovarian Cancer (PRNewswire) - "The preclinical study demonstrated that JIN-001, when combined with the chemotherapeutic agent cisplatin, significantly enhanced tumor suppression compared to cisplatin alone. Notably, even at low concentrations (≤0.1 μM), JIN-001 enhanced the antitumor activity of cisplatin against both cisplatin-sensitive and cisplatin-resistant ovarian cancer cells, compared to cisplatin alone. Moreover, the combination therapy significantly reduced the expression of key signaling proteins related to cisplatin resistance, contributing to a sustained antitumor effect. Based on these promising results, J INTS BIO is planning additional preclinical studies and aims to rapidly advance JIN-001 into clinical trials, with the goal of establishing a new standard of care for the treatment of refractory and multidrug-resistant ovarian cancer." "

Platinum resistant • Preclinical • Ovarian Cancer

J INTS BIO and MD Anderson Collaborate on the Development of Brain Tumor Treatment 'JIN-001' - Enhancing Radiation and Chemotherapy Efficacy (PRNewswire) - "J INTS BIO announced research findings on its innovative brain tumor treatment, 'JIN-001,' developed in collaboration with MD Anderson Cancer Center, at the 2024 Society of Neuro-Oncology (SNO) Annual Meeting in Texas, USA. MD Anderson is a globally renowned cancer research institution, and J INTS BIO has partnered with it since 2021 to advance this groundbreaking therapy."

Licensing / partnership • Glioblastoma

A genome-wide CRISPR/Cas9 screen in glioblastoma stem cells unveils synthetic lethal interactions and resistance mechanisms of JIN001, a blood-brain barrier-penetrant Hsp90 inhibitor (SNO 2024) - "Validation studies for the top synthetic lethal targets are underway to confirm the identified interactions and will be presented. This CRISPR-Cas9 screen offers valuable insights into JIN001's therapeutic potential, reveals new combination strategies to overcome resistance to Hsp90 inhibitors and for use of these agents in other cancers, and paves the way for the development of more effective GBM combination treatment strategies."

Synthetic lethality • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor • CDC37

Enhanced chemo and radio-sensitization of gliomas by HSP90 inhibition with JIN-001, a novel blood-brain barrier penetrant HSP90 inhibitor. (SNO 2024) - "Here, we determined the effects of JIN-001 mediated HSP90 inhibition on alkylator and radiation induced DNA damage. Using a panel of patient-derived glioma stem cells (GSCs) we determined the synergy scores for cell viability of JIN-001 (0.1µM to 0.5µM) in combination with radiation (RT) and Temozolomide (TMZ). Through a comprehensive analysis, we demonstrated that HSP90 inhibitor JIN-001 sensitizes glioma cells to radio-chemotherapy including in human glioma tissue. Our study underscores the potential of combining JIN-001 with standard therapies in glioma treatment in future clinical trials for patients with glioblastoma."

Brain Cancer • CNS Tumor • Glioblastoma • Glioma • Oncology • Solid Tumor • CDC37

J INTS BIO Presents Interim Results from the Preclinical Study of 'JIN-001' in Refractory Ovarian Cancer: A Promising Solution for Overcoming Drug Resistance (PRNewswire) - "J INTS BIO...has revealed interim preclinical results of its second-generation synthetic HSP90 inhibitor, JIN-001, at the ENA (EORTC-NCI-AACR) Symposium....When JIN-001 was used alongside paclitaxel, the IC50 value of paclitaxel in the resistant OV90/PTX200 cell line decreased from 0.204 μM to 0.043 μM, demonstrating a substantial improvement in therapeutic efficacy....The interim results strongly suggest that JIN-001 has the potential to serve as a breakthrough companion therapy for patients with ovarian cancer....Collaborative research with MD Anderson Cancer Center on JIN-001's potential in glioblastoma has already yielded positive preclinical results, with a Phase 1 trial anticipated in 2025."

New P1 trial • Preclinical • Glioblastoma • Ovarian Cancer

Synergistic effect of JIN-001, a novel HPS90 selective inhibitor, with platinum or paclitaxel on multi-resistant ovarian cancer (EORTC-NCI-AACR 2024) - "To generate a drug resistant subline, cells were exposed to IC50 concentration of paclitaxel (PTX) or cisplatin (Cis) and gradually exposed to higher concentrations. The drug resistance sub-cell lines were used including PTX200, PTX100, or CisR, respectively...This suggests the benefit of shutting down tumor adaptation while eradicating the tumor rather than focusing on tumor eradication in the short term. Further studies are needed to demonstrate the ability of JIN-001 to retard the tumor's ability to adapt and develop treatment resistance."

Oncology • Ovarian Cancer • Solid Tumor • CDC37 • PRDX2

Phase I, FIH, MTD for MPT0B640, Multi-centre, Open-label, Subject With Locally Advanced or Metastatic Solid Malignancies (clinicaltrials.gov) - P1 | N=0 | Withdrawn | Sponsor: J Ints Bio | N=15 ➔ 0 | Trial completion date: Nov 2022 ➔ Nov 2027 | Not yet recruiting ➔ Withdrawn | Trial primary completion date: Nov 2022 ➔ Nov 2027

Enrollment change • Metastases • Trial completion date • Trial primary completion date • Trial withdrawal • Breast Cancer • Gastrointestinal Cancer • Hepatocellular Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

JINTS BIO, M.D Anderson Cancer Center joint development - oral HSP90 inhibitor ’JIN-001’, presentation of preclinical assessment at 2022 SNO Annual Meeting (PRNewswire) - "J INTS BIO announced that the preclinical assessment of JIN-001 or MPT0B640, a novel, orally administered 2nd generation HSP90 (heat shock protein 90) inhibitor, was presented during the 2022 edition of the Society for Neuro-Oncology Conference, held in Tampa, Florida from 17th to 20th November....Preclinical data showed that JIN-001 is potent against a wide spectrum of diverse glioma cell lines in a dose and time dependent manner, by downregulating client proteins essential for glioma cell survival. In addition, JIN-001 is highly penetrant of the normal Blood Brain Barrier with greater drug exposure in the brain versus the plasma, and this has resulted in a significant survival benefit in intracranial mouse model. J INTS BIO is confident that JIN-001 will benefit patients with GBM and in collaboration with MD Anderson, to start human trials in GBM patients in 2023."

New trial • Preclinical • Brain Cancer • CNS Tumor • Glioblastoma • Glioma • Oncology

Preclinical assessment of the efficacy of MPT0B640, an orally bioavailable small molecule HSP90 inhibitor, against Gliomas (SNO 2022) - "MPT0B640 is a potent HSP90 inhibitor that has potent antitumor activity against genetically heterogeneous gliomas in vitro, effectively crosses the intact BBB and demonstrates target inhibition warranting further investigation for treatment of gliomas."

Preclinical • Brain Cancer • Glioma • Oncology • Solid Tumor • ANXA5

Heat Shock Protein Inhibitor- MPT0B640 for COVID-19 Infection (clinicaltrials.gov) - P1; N=0; Withdrawn; Sponsor: J Ints Bio; N=15 ➔ 0; Not yet recruiting ➔ Withdrawn

Enrollment change • Trial withdrawal • Infectious Disease • Novel Coronavirus Disease • PCR

Phase I, FIH, MTD for MPT0B640, Multi-centre, Open-label, Subject With Locally Advanced or Metastatic Solid Malignancies (clinicaltrials.gov) - P1; N=15; Not yet recruiting; Sponsor: Joseah Bio; Trial completion date: Nov 2021 ➔ Nov 2022; Initiation date: Dec 2020 ➔ Dec 2021; Trial primary completion date: Nov 2021 ➔ Nov 2022

Clinical • Trial completion date • Trial initiation date • Trial primary completion date • Breast Cancer • Gastrointestinal Cancer • Hepatocellular Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Heat Shock Protein Inhibitor- MPT0B640 for COVID-19 Infection (clinicaltrials.gov) - P1; N=15; Not yet recruiting; Sponsor: Joseah Bio; Trial completion date: Dec 2021 ➔ Dec 2022; Initiation date: Dec 2020 ➔ Dec 2021; Trial primary completion date: Dec 2021 ➔ Dec 2022

Clinical • Trial completion date • Trial initiation date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • PCR

Heat Shock Protein Inhibitor- MPT0B640 for COVID-19 Infection (clinicaltrials.gov) - P1; N=15; Not yet recruiting; Sponsor: Joseah Bio

New P1 trial • Infectious Disease • Novel Coronavirus Disease

Phase I, FIH, MTD for MPT0B640, Multi-centre, Open-label, Subject With Locally Advanced or Metastatic Solid Malignancies (clinicaltrials.gov) - P1; N=15; Not yet recruiting; Sponsor: Joseah Bio; Trial completion date: Mar 2021 ➔ Nov 2021; Initiation date: Jun 2020 ➔ Dec 2020; Trial primary completion date: Nov 2020 ➔ Nov 2021

Clinical • Trial completion date • Trial initiation date • Trial primary completion date • Breast Cancer • Gastrointestinal Cancer • Hepatocellular Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Phase I, FIH, MTD for MPT0B640 (clinicaltrials.gov) - P1; N=15; Not yet recruiting; Sponsor: Joseah Bio

Clinical • New P1 trial